Lung Cancer Genomic Testing Market worth $1.73 billion by 2030, growing at a CAGR of 8.00% - Exclusive Report by 360iResearch

The "Lung Cancer Genomic Testing Market by Technology (Fluorescence In Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction), Sample Type (Liquid Biopsy, Tissue Biopsy), Panel Type, End User - Global Forecast 2024-2030" report has been added to 360iResearch.com's offering.

The Global Lung Cancer Genomic Testing Market to grow from USD 1.01 billion in 2023 to USD 1.73 billion by 2030, at a CAGR of 8.00%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/lung-cancer-genomic-testing?utm_source=openpr&utm_medium=referral&utm_campaign=sample

The lung cancer genomic testing involves genomic tests that identify mutations, rearrangements, and amplifications in cancerous cells, which can help in the tailored treatment of lung cancer. These tests provide critical insights into the genetic mutations in the tumor tissue, which can influence treatment decisions and patient outcomes. Key end-users include oncology departments in hospitals, cancer research institutions, diagnostic labs, and biopharma companies involved in drug discovery. Products range from consumables to sophisticated software for genomic data analysis. The expansion is attributed to factors such as the rising incidence of lung cancer, advancements in sequencing technology, and the growing recognition of personalized medicine. Opportunities are proliferating with advancements such as non-invasive liquid biopsies, AI integration, and international genomic data collaborations. However, restraints, including high costs, limited access in underdeveloped areas, complex regulatory barriers, and the necessity for expertise in data interpretation, hamper growth. Key players are expected to focus on innovation and research by developing cost-effective tests, increasing the accessibility of testing, improving the predictive accuracy of tests, and expanding the application of genomic testing in early cancer detection. Collaborative efforts with healthcare entities and regulatory bodies are essential to cement the role of genomic testing in improving patient care in oncology. Reimbursement policies and government initiatives promoting cancer genomics research also favor market expansion.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Lung Cancer Genomic Testing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Lung Cancer Genomic Testing Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/lung-cancer-genomic-testing?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Lung Cancer Genomic Testing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Technology, market is studied across Fluorescence In Situ Hybridization, Next-Generation Sequencing, and Polymerase Chain Reaction. The Fluorescence In Situ Hybridization is projected to witness significant market share during forecast period.

Based on Sample Type, market is studied across Liquid Biopsy and Tissue Biopsy. The Liquid Biopsy is projected to witness significant market share during forecast period.

Based on Panel Type, market is studied across Multi-Gene Panel and Single-Gene Panel. The Multi-Gene Panel is projected to witness significant market share during forecast period.

Based on End User, market is studied across Diagnostic Laboratories, Hospitals/Clinics, and Research Organization. The Diagnostic Laboratories is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Lung Cancer Genomic Testing Market, by Technology
7. Lung Cancer Genomic Testing Market, by Sample Type
8. Lung Cancer Genomic Testing Market, by Panel Type
9. Lung Cancer Genomic Testing Market, by End User
10. Americas Lung Cancer Genomic Testing Market
11. Asia-Pacific Lung Cancer Genomic Testing Market
12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Lung Cancer Genomic Testing Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Lung Cancer Genomic Testing Market?
3. What is the competitive strategic window for opportunities in the Lung Cancer Genomic Testing Market?
4. What are the technology trends and regulatory frameworks in the Lung Cancer Genomic Testing Market?
5. What is the market share of the leading vendors in the Lung Cancer Genomic Testing Market?
6. What modes and strategic moves are considered suitable for entering the Lung Cancer Genomic Testing Market?

Read More @ https://www.360iresearch.com/library/intelligence/lung-cancer-genomic-testing?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.